A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia

被引：0
|
作者：
Dombret, Herve [1 ]
Preudhomme, Claude [2 ]
Berthon, Celine [2 ]
Raffoux, Emmanuel [1 ]
Thomas, Xavier [3 ]
Vey, Norbert [4 ]
Gomez-Roca, Carlos [5 ]
Ethell, Mark [6 ]
Yee, Karen [7 ]
Bourdel, Fabrice [8 ]
Herait, Patrice [9 ]
Michallet, Mauricette [3 ]
Recher, Christian [5 ]
Roumier, Christophe [2 ]
Quesnel, Bruno [10 ]
机构：
[1] Hop St Louis, APHP, Paris, France
[2] Hop Claude Huriez, Lille, France
[3] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France
[4] Inst J Paoli I Calmettes, F-13009 Marseille, France
[5] Inst Univ Canc Toulouse, Toulouse, France
[6] Royal Marsden Hosp, London SW3 6JJ, England
[7] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[8] OTD, Clichy, France
[9] Oncoethix, Lausanne, Switzerland
[10] CHRU Lille, Hop Claude Huriez, F-59037 Lille, France
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies
    Thieblemont, Catherine
    Stathis, Anastasios
    Inghirami, Giorgio
    Karlin, Lionel
    Morschhauser, Franck
    Gleeson, Mary
    Broussais, Florence
    Amorim, Sandy
    Salles, Gilles
    Facon, Thierry
    Cunningham, David
    Vey, Norbert
    Bourdel, Fabrice
    Herait, Patrice
    Zucca, Emanuele
    [J]. BLOOD, 2014, 124 (21)
  • [2] Development of the BET bromodomain inhibitor OTX015
    Noel, J. Kay
    Iwata, Kazunori
    Ooike, Shinsuke
    Sugahara, Kunio
    Nakamura, Hideo
    Daibata, Masanori
    [J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [3] Activity of OTX015 (MK-8628), a BET-Bromodomain Inhibitor, in Acute Myeloid Leukemia (AML) Progenitor Cells
    Roulin, Louise
    Ali, Ashfaq
    Masse, Aline
    Coude, Marie-Magdelaine
    Bluteau, Dominique
    Braun, Thorsten
    Berrou, Jeanning
    Bluteau, Olivier
    Delord, Marc
    Riveiro, Maria Eugenia
    Herait, Patrice Edouard
    Soulier, Jean
    Baruchel, Andre
    Gardin, Claude
    Dombret, Herve
    Itzykson, Raphael
    [J]. BLOOD, 2015, 126 (23)
  • [4] OTX015, a novel BET-bromodomain (BET-BRD) inhibitor, is a promising anticancer agent for human glioblastoma
    Ouafik, L.
    Berenguer, C.
    Cayol, M.
    Astorgues-Xerri, L.
    Bekradda, M.
    Odore, E.
    Rezai, K.
    Riveiro, M. E.
    Cvitkovic, E.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 153 - 153
  • [5] Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
    Berthon, Celine
    Raffoux, Emmanuel
    Thomas, Xavier
    Vey, Norbert
    Gomez-Roca, Carlos
    Yee, Karen
    Taussig, David Christopher
    Rezai, Keyvan
    Roumier, Christophe
    Herait, Patrice
    Kahatt, Carmen
    Quesnel, Bruno
    Michallet, Mauricette
    Recher, Christian
    Lokiec, Francois
    Preudhomme, Claude
    Dombret, Herve
    [J]. LANCET HAEMATOLOGY, 2016, 3 (04): : E186 - E195
  • [6] Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies
    Stathis, A.
    Quesnel, B.
    Amorim, S.
    Thieblemont, C.
    Zucca, E.
    Raffoux, E.
    Dombret, H.
    Peng, Y.
    Palumbo, A.
    Vey, N.
    Thomas, X.
    Michallet, M.
    Gomez-Roca, C.
    Recher, C.
    Karlin, L.
    Yee, K.
    Rezai, K.
    Preudhomme, C.
    Facon, T.
    Herait, R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 196 - 196
  • [7] The BET Bromodomain Inhibitor OTX015 Synergizes with Targeted Agents in Multiple Myeloma
    Gu, Jie
    Song, Sha
    Han, Huiying
    Xu, Hongxia
    Fan, Gao
    Qian, Chen'ao
    Qiu, Yingchun
    Zhou, Wenqi
    Zhuang, Wenzhuo
    Li, Bingzong
    [J]. MOLECULAR PHARMACEUTICS, 2018, 15 (11) : 5387 - 5396
  • [8] OTX015, a novel BET-bromodomain (BET-BRD) inhibitor, displays antitumoral effects in orthotopic and heterotopic models of human glioblastoma
    Astorgues-xerri, Lucile
    Berenger, Caroline
    Cayol, Mylene
    Bekradda, Mohamed
    Odore, Elodie
    Rezai, Keyvan
    Cvitkovic, Esteban
    Riveiro, Maria E.
    Ouafik, L'Houcine
    [J]. CANCER RESEARCH, 2015, 75
  • [9] Preclinical Evaluation of the BET-Bromodomain (BET-BRD) Inhibitor OTX015 in Leukemia Cell Lines Harboring the JAK2 V617F Mutation
    Riveiro, Maria Eugenia
    Astorgues-Xerri, Lucile
    Canet-jourdan, Charlotte
    Bekradda, Mohamed
    Cvitkovic, Esteban
    Herait, Patrice
    Raymond, Eric
    [J]. BLOOD, 2014, 124 (21)
  • [10] OTX015, a BET-bromodomain (BET-BRD) inhibitor, potentiates the in vitro effects of chemotherapy drugs and targeted agents in human leukemic cell lines
    Astorgues-Xerri, L.
    Canet-Jourdan, C.
    Bekradda, M.
    Cvitkovic, E.
    Herait, P.
    Raymond, E.
    Riveiro, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 183 - 183
12345